Streetbeat News

Products Services

CYBN

Cybin is set to commence its Phase 3 pivotal program for CYB003 in late summer, following a Type B Initial Breakthrough Therapy meeting with the FDA. The company has selected 30 clinical sites across the US and Europe. In Phase 2, CYB003 showed a 75% remission rate from depression four months after two 16mg doses. Cybin expects to report 12-month efficacy data from Phase 2 in Q4 this year.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:37 am

PBM

Psyence Biomedical and Optimi Health have signed a non-binding letter of intent to collaborate on global psilocybin drug development. Optimi Health will become the exclusive supplier of GMP non-synthetic psilocybin extract for Psyence's initiatives.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:36 am

NRXP

NRx Pharmaceuticals has secured up to $16 million in convertible debt financing from an institutional investor. The funds will support the 2024 New Drug Application filing for its two lead products, NRX-100 and NRX-101, and will also be used to retire existing debt from Streeterville Capital.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:36 am

ABEO

The Centers for Medicare and Medicaid Services (CMS) has granted a product-specific procedure code ICD-10-PCS for Abeona Therapeutics' investigational gene therapy, Prademagene Zamikeracel (Pz-cel). This code will facilitate efficient documentation, billing, and analysis of inpatient hospital procedures using Pz-cel if it receives U.S. marketing approval. The code will be effective from October 1, 2024.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:34 am

PSTV

Plus Therapeutics announced that its CNSide Leptomeningeal Metastases FORSEE Trial met key primary and secondary endpoints. The trial demonstrated that CNSide influenced treatment decisions in over 90% of cases, surpassing the 20% primary endpoint target. The data were presented at the 2024 Society for NeuroOncology (SNO)/American Society for Clinical Oncology (ASCO) CNS Metastases Conference.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:32 am

TSLA

Elon Musk, CEO of Tesla Inc. (NASDAQ:TSLA), emphasized that better products, not climate change concerns, will drive the transition to electric vehicles (EVs). Musk's comments came after a Spaces interview with Donald Trump, where Musk stated his moderate views on climate change and the importance of sustainable energy.

Portfolio Pulse from Anan Ashraf

August 13, 2024 | 11:25 am

NVDA

Nvidia's stock has risen 119% year-to-date despite recent volatility and a dip to around $100. Analysts from Bank of America and UBS have endorsed Nvidia as a 'top pick' due to expected growth from increased AI spending. Concerns over potential U.S. export restrictions to China and a delay in launching Blackwell chips have impacted the stock. However, Nvidia is expected to provide a key update in its Q2 earnings report on August 28, which could ease investor concerns. The Fed's upcoming decisions on interest rates are also seen as crucial for Nvidia's stock performance.

Portfolio Pulse from Zaheer Anwari

August 13, 2024 | 11:24 am

POAI

Predictive Oncology has expanded the applications of its AI platform to address patient heterogeneity, de-risk drug discovery, and accelerate pipeline development. The platform supports biomarker discovery, clinical trial optimization, and target validation, increasing the Probability of Technical Success.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:16 am

SOTK

Sono-Tek Corporation has secured an additional $2.95 million order from a clean energy customer, indicating strong demand for its products in the clean energy sector.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:13 am

LASE

Laser Photonics and Boston Engineering have formed a partnership to integrate laser technologies into autonomous robots for the naval defense industry.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:12 am